Clinical Trial Update: Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study [Phase 2]

View source ↗

Summary

This clinical trial update notes a Phase 2 study evaluating metronomic temozolomide in unfit patients with advanced neuroendocrine tumors (NENs). The trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: European Institute of Oncology | Conditions: Neuroendocrine Tumors, Frailty | Phase 2 | Status: RECRUITING